New progress and challenge in gynecological cancer

Wang, Danbo

doi:10.21037/atm-2021-45

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite remarkable progress in cancer research and treatment, the disease continues to inflict a significant toll, with demographic and epidemiological shifts leading to a rise in cancer incidence, with nearly two million new cases diagnosed worldwide in 2020 alone [ 1 – 3 ]. Gynecological cancers comprise a group of neoplasms that arise in the reproductive or genital organs of women, predominantly cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC) [ 4 ]. They represent a worldwide public health problem, and according to Global Cancer Incidence, Mortality, and Prevalence (GLOBOCAN), there were 1,398,601 diagnosed cases of gynecological cancer and 671,875 associated deaths worldwide in 2020 [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients

de Moraes,

Sudo,

Souza

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Female gynecological cancers represent a serious public health problem, with 1,398,601 new diagnoses and 671,875 deaths per year worldwide. Antipsychotics are often used in psychiatric disorders, including schizophrenia, bipolar disorder, and major depression. It is estimated that the prescription of these drugs is linked to 1,800 deaths a year in the United States, but their association with cancer remains controversial. Methods We searched PubMed, Scopus, and Web of Science databases for studies reporting the correlation in the incidence risk of gynecological cancer by antipsychotic use. We used DerSimonian and Laird random-effect models to compute logit transformed odds ratio (OR) for the primary binary endpoint with 95% confidence interval (CI). Heterogeneity was assessed through effect size width along with I-squared and Tau-squared statistics. Review Manager 5.4.1. was used for statistical analyses. A p-value of < 0.05 denoted statistically significant. Results 50,402 patients were included, of whom 778 (1,54%) took antipsychotic medication for at least 1 year. 1,086 (2,15%) with ovarian cancer and 49,316 (97,85%) with endometrial cancer. Antipsychotic use (OR 1.50; 1.06 to 2.13 95% CI; p-value 0.02), hypertension (OR 1.50; 95% CI 1.06 to 2.13; p-value < 0.01), nulliparity (OR 1.98; 95% CI 1.53 to 2.57; p-value < 0.01) and multiparity (OR 0.53; 95% CI 0.41 to 0.69; p-value < 0.01) showed significantly different distributions between groups of cancer and cancer-free patients. The primary endpoint of incidence risk of gynecological cancer by antipsychotic therapy showed a statistically significant difference (OR 1.67; 95% CI 1.02 to 2.73; p-value < 0.05) against the use of antipsychotic drugs. Conclusions Our meta-analysis showed that the use of antipsychotic drugs increases the risk of gynecological cancers, particularly endometrial cancer. This result should be weighed against the potential effects of treatment for a balanced prescribing decision.

show abstract

Section: Introductionmentioning

confidence: 99%

The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients

de Moraes,

Sudo,

Souza

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Gynecological cancer comprises a series of heterogeneous cancers, predominantly cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC) [ 1 ]. Globally, gynecological cancer is a serious public health issue, and according to the Global Cancer Incidence, Mortality, and Prevalence (GLOBOCAN) estimates, there were 1,398,601 gynecological cancer cases diagnosed and 671,875 associated deaths worldwide in 2020 [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic and clinicopathological impacts of Controlling Nutritional Status (CONUT) score on patients with gynecological cancer: a meta-analysis

Niu

Yan

2023

Nutr J

View full text Add to dashboard Cite

Background The Controlling Nutritional Status (CONUT) score has proven to be a potential biomarker for determining the prognosis of patients with various types of cancer. Its value in determining the prognosis of patients with gynecological cancer, however, remains unknown. The present study was a meta-analysis that aimed to evaluate the prognostic and clinicopathological significance of the CONUT score in gynecological cancer. Methods The Embase, PubMed, Cochrane Library, Web of Science, and China National Knowledge Infrastructure databases were comprehensively searched through November 22, 2022. A pooled hazard ratio (HR), together with a 95% confidence interval (CI), was used to determine whether the CONUT score had prognostic value in terms of survival outcomes. Using odds ratios (ORs) and 95% CIs, we estimated the relationship between the CONUT score and clinicopathological characteristics of gynecological cancer. Results We evaluated 6 articles, involving a total of 2,569 cases, in the present study. According to the results of our analyses, higher CONUT scores were significantly correlated with decreased overall survival (OS) (n = 6; HR = 1.52; 95% CI = 1.13–2.04; P = 0.006; I2 = 57.4%; Ph = 0.038) and progression-free survival (PFS) (n = 4; HR = 1.51; 95% CI = 1.25–1.84; P < 0.001; I2 = 0; Ph = 0.682) in gynecological cancer. Moreover, higher CONUT scores were significantly correlated with a histological grade of G3 (n = 3; OR = 1.76; 95% CI = 1.18–2.62; P = 0.006; I2 = 0; Ph = 0.980), a tumor size ≥ 4 cm (n = 2; OR = 1.50; 95% CI = 1.12–2.01; P = 0.007; I2 = 0; Ph = 0.721), and an advanced International Federation of Gynecology and Obstetrics (FIGO) stage (n = 2; OR = 2.52; 95% CI = 1.54–4.11; P < 0.001; I2 = 45.5%; Ph = 0.175). The correlation between the CONUT score and lymph node metastasis, however, was not significant. Conclusions Higher CONUT scores were significantly correlated with decreased OS and PFS in gynecological cancer. The CONUT score, therefore, is a promising and cost-effective biomarker for predicting survival outcomes in gynecological cancer.

show abstract

“…The still ambiguous pathogenesis, heterogeneity of diseases and difficult diagnostics mean that gynecological cancers are often diagnosed at a late stage. Therefore, research is still underway on new, sensitive, and specific biomarkers to enable quick, non-invasive diagnostics in the early stages of the disease, prediction, and precise monitoring of therapy [ 5 , 6 , 7 , 8 ]. MicroRNAs, which have been studied for many years, provide hope.…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs as Potential Biomarkers in Gynecological Cancers

2023

View full text Add to dashboard Cite

MicroRNAs are non-coding transcripts that, thanks to the ability to regulate the mRNA of target genes, can affect the expression of genes encoding tumor suppressors and oncogenes. They can control many important cellular processes, including apoptosis, differentiation, growth, division, and metabolism. Therefore, miRNAs play an important role in the development of many cancers, including gynecological cancers. Ovarian cancer, endometrial cancer, cervical cancer, and vulvar cancer are the most common cancers in women and are a frequent cause of death. The heterogeneity of the pathogenesis of these gynecological diseases makes the diagnostic process a significant obstacle for modern medicine. To date, many studies have been carried out, in which particular attention has been paid to the molecular pathomechanism of these diseases, with particular emphasis on miRNAs. To date, the changed profile of many miRNAs, which influenced the promotion of proliferation, migration, invasion processes and the simultaneous inhibition of programmed cell death, has been proven many times. Detailed understanding of the molecular effects of miRNAs in the above-mentioned gynecological cancers will enable the development of potential predictive and prognostic biomarkers, as well as the optimization of the diagnostic process.

show abstract

New progress and challenge in gynecological cancer

Cited by 3 publications

References 8 publications

The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients

The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients

Prognostic and clinicopathological impacts of Controlling Nutritional Status (CONUT) score on patients with gynecological cancer: a meta-analysis

MicroRNAs as Potential Biomarkers in Gynecological Cancers

Contact Info

Product

Resources

About